Search
Partners
Patient organizations
Scientific networks
National societies
Sponsors
Media partnerships
Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)
CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.
Read moreSWG Educational Activities
EICMLThe 2023 EICML meeting took place in Naples in May 2023. Fifty-five physicians and scientists met at the Palazzo Alabardieri in central Naples to spend two days discussing emerging data and developing collaborations.
Read moreHospital pharmacists and regulators lead the way on shortages
EHA welcomes initiatives but calls for more focus on causes
Medicine shortages have a negative impact on the quality and cost of treatments and on patient access to the best possible care.
Mini-hormone fights iron
Iron overload commonly leads to organ damage and even death. Currently available treatments for iron overload are burdensome or cause side effects.
Read moreEHA Issues Recommendations on Mild to Moderate Bleeding Disorders
HemaSphere presents first in a series of Consensus Reports on Diagnosis of Inherited Bleeding Problems
For hematologists, it can be challenging to make the correct diagnosis in patients with bleeding problems – or even to determine whether there is any bleeding…
Cancer Medicines Forum workshop April 5: a way forward for treatment optimization
The Cancer Medicines Forum (CMF) is hosted by the European Medicines Agency (EMA) in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC).
Read moreEHA Lymphoma Group
The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.
Read moreEuropean Research Initiative on CLL (ERIC)
ERIC is devoted to improving the outcome of patients with Chronic Lymphocytic Leukemia (CLL) and related diseases. The objectives of ERIC are to promote:
Research in all aspects of chronic lymphocytic leukemia and related diseases.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- »